[Therapy of bronchopulmonary infection in smokers].

Abstract

The efficacy and safety of Cifran OD, a new dosage form of ciprofloxacin with prolonged action were studied in the treatment of patients with bronchopulmonary infection (n=23). The drug was used orally in a dose of 1 g once a day. The patients were divided into 2 groups: group 1 included patients with aggravation of chronic bronchitis and group 2 included patients with bacterial pneumonia. The recovery was stated in 77.7% of the patients in group 1, the other 26.3% of the patients showed clinical improvement. In the patients with pneumonia (group 2) the recovery was recorded in 100% of the cases. No significant side effects were observed.

• Authors: V I Sokolova, V A Orlov, Iu V Surkova, V A Shenderovich, L B Smirnova
• Journal: Antibiotiki i khimioterapiia = Antibiotics and chemoterapy [sic] (Antibiot Khimioter) Vol. 49 Issue 3 Pg. 22-5 ( 2004) ISSN: 0235-2990 [Print] Russia (Federation)
• Vernacular Title: Terapiia bronkholegochnykh infektsiĭ u kuril'shchikov.
• PMID: 15344393 (Publication Type: Clinical Trial, English Abstract, Journal Article)

Chemical References

• Anti-Bacterial Agents
• Ciprofloxacin

Topics

• Adult
• Aged
• Anti-Bacterial Agents (therapeutic use)
• Bronchitis, Chronic (drug therapy)
• Ciprofloxacin (therapeutic use)
• Colony Count, Microbial
• Community-Acquired Infections (drug therapy, microbiology)
• Female
• Humans
• Male
• Middle Aged
• Pneumonia, Bacterial (drug therapy, microbiology)